On July 14, 2026, ENvue Medical, Inc. announced a series of board of directors changes, including the voluntary resignations of David Johnson and Nino Pionati. The Board appointed Zvi Joseph and Lior Buchman to fill the vacancies, with Joseph and Buchman both serving on the Audit Committee. Zeev Rotstein, M.D., an existing board member, was appointed as the new Chairman of the Board. ENvue Medical, Inc. operates in the medical technology industry and develops medical devices for skin and tissue engineering.

ENvue Medical, Inc. received a Nasdaq Staff Determination Letter on July 10, 2026, notifying the company of its failure to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. Due to a prior 1-for-10 reverse stock split on August 12, 2025, the company is ineligible for a 180-day compliance period. The company intends to appeal the determination via a hearing before the Panel. ENvue Medical, Inc. operates in the medical technology industry and develops medical devices for skin-related conditions.